Pediatrix Medical Group, Inc.
Close on Oct 19, 2026
- Market cap
- $2.22B
- P/E (TTM)
- 13.1
- Dividend yield
- –
About Pediatrix Medical
Services-Hospitals, SIC 8060
Pediatrix Medical Group, Inc. delivers specialized physician services focused on newborn, maternal-fetal, and pediatric subspecialty clinical care. Its core clinical offerings include hospital-based neonatal care in neonatal intensive care units, maternal-fetal and obstetrical medical services for complicated pregnancies, pediatric intensive care, inpatient pediatric care, and pediatric surgery. The company additionally operates a newborn hearing screening program, conducts clinical research, and delivers administrative practice support and telehealth solutions. Its primary customers include for-profit and not-for-profit hospital partners, health systems, and referring physicians.
The company operates a national network comprising approximately 2,295 affiliated physicians who provide clinical services across 37 states. Its clinical footprint spans clinical staffing and management at over 360 neonatal intensive care units in 32 states, pediatric intensive care units at approximately 60 hospitals, and partnerships with around 400 hospitals nationwide. Pediatrix Medical Group maintains its principal executive offices in Sunrise, Florida.
Summary of the business section of Pediatrix Medical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Pediatrix Medical Group, Inc.
- Founded
- 1979
- Headquarters
- Sunrise, FL
- Address
- 1301 Concord Terrace 33323
- Phone
- (954) 384-0175
- Website
- www.pediatrix.com
- Industry
- Services-Hospitals
- Incorporated in
- Florida
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Miami, Florida
Stock & identifiers
- Ticker
- MD
- Exchange
- NYSE
- Shares outstanding
- 81M, Jul 31, 2026
- Public float
- $899.92M, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Dec 20, 2013; 2-for-1, Dec 19, 2013; 2-for-1, Apr 28, 2006
- SEC CIK
- 893949
- CUSIP
- 58502B106
- ISIN
- US58502B1061
- EIN
- 26-3667538
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mark S. Ordan | Chief Executive Officer, Director | 313,710 |
| David Haddock | EVP, GC & Corp Sec | 20,036 |
| Mary Ann E. Moore | EVP, GC, Chief Admin Off & Sec | 189,890 |
| Don Gregory Neeb | EVP, Chief Invest & Strategy | 137,231 |
| Kasandra H. Rossi | EVP, CFO and Treasurer | 105,100 |
| Laura A. Linynsky | Director | 33,900 |
| Sylvia Jean Young | Director | 29,786 |
| Shirley A. Weis | Director | 19,095 |
| Kurt Douglas Newman | Director | 17,405 |
| Guy P. Sansone | Director | 87,416 |
| Thomas McEachin | Director | 73,741 |
| Michael A. Rucker | Director | 66,769 |
| John M. Starcher Jr. | Director | 73,732 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr Ordan | $14.14M | $24.89M | $3.40M | $87 | $78 |
| FY2024 Dr Swift | $3.30M | $4.42M | $2.08M | $53 | $78 |
| FY2024 First PEO | $3.30M | $4.42M | $2.08M | $53 | $78 |
| FY2023 Dr Swift | $2.24M | $1.62M | $1.72M | $38 | $76 |
| FY2023 Dr.Swift | $2.24M | $1.62M | $1.72M | $38 | $76 |
| FY2023 First PEO | $2.24M | $1.62M | $1.72M | $38 | $76 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Corporate history
Events identified from SEC filings